J. Pharm. Pharmacogn. Res., vol. 14, no. 4, Article ID 2545, Jul-Aug 2026.
DOI: https://doi.org/10.56499/jppres_14.4.2545Original Article
Integrated network pharmacology and molecular simulation analysis of colchicine in coronary in-stent restenosis
[Análisis integrado de farmacología de redes y simulación molecular de la colchicina en la reestenosis coronaria intrastent]
Suryono Suryono1*, Muhammad I. Amien2, Achmad I. Tohari2,3, Antonius D. Saputra2, Muhammad R. Fahrudin Hidayat2, Muhammad N. Hibatullah2, Hazbina F. Ramadhan4, Muhammad F. Hibatulloh2
1Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Jember - Dr. Soebandi General Hospital- Jember, Indonesia.
2Faculty of Medicine, Universitas Jember, Jember, Indonesia.
3Department of Epidemiology and Preventive Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan.
4Kalisat General Hospital, Jember, Indonesia.
*E-mail: suryonofiha@gmail.com
Abstract
Context: In-stent restenosis (ISR) remains a major complication following percutaneous coronary intervention. Increasing evidence suggests that genetic and inflammatory mechanisms contribute to ISR pathogenesis. Colchicine has demonstrated anti-inflammatory effects in cardiovascular diseases; however, its molecular targets in ISR remain unclear.
Aims: To identify potential molecular targets and signaling pathways through which colchicine may modulate ISR using integrated computational approaches.
Methods: ISR-related genes were retrieved from GeneCards, OMIM, and CTD databases. Colchicine targets were predicted using SwissTargetPrediction, BindingDB, SEASearch, and DrugBank. Overlapping genes were analyzed using protein–protein interaction networks and hub gene identification. Functional enrichment analysis was performed using GO and KEGG pathways. Molecular docking and 200 ns molecular dynamics simulations were conducted to evaluate binding stability. Binding free energies were calculated using MM-GBSA.
Results: Sixteen overlapping targets were identified, and ten hub genes were prioritized. Docking analysis demonstrated moderate binding affinity of colchicine toward CYP3A4, TUBB1, and CYP2B6 (−6.9 to −7.4 kcal/mol). Molecular dynamics simulations indicated stable ligand–protein complexes with RMSD values below 2.5 Å. MM-GBSA analysis suggested favorable binding energies, particularly for TUBB1.
Conclusions: Colchicine was predicted to interact with several ISR-associated targets and pathways, providing a computational basis for further experimental validation.
Keywords: drug repurposing; in-stent restenosis; molecular docking simulation; molecular dynamics simulation; network pharmacology.

Resumen
Contexto: La reestenosis intrastent (ISR) sigue siendo una complicación importante tras la intervención coronaria percutánea. Evidencias crecientes sugieren que los mecanismos genéticos e inflamatorios contribuyen a la patogénesis de la ISR. La colchicina ha demostrado efectos antiinflamatorios en enfermedades cardiovasculares; sin embargo, sus dianas moleculares en la ISR aún no están completamente aclaradas.
Objetivos: Identificar posibles dianas moleculares y vías de señalización a través de las cuales la colchicina podría modular la ISR mediante enfoques computacionales integrados.
Métodos: Los genes relacionados con la ISR se obtuvieron de las bases de datos GeneCards, OMIM y CTD. Las dianas de la colchicina se predijeron mediante SwissTargetPrediction, BindingDB, SEA Search y DrugBank. Los genes superpuestos se analizaron mediante redes de interacción proteína‑proteína e identificación de genes centrales (hub genes). El análisis de enriquecimiento funcional se realizó mediante las bases de datos GO y KEGG. Se llevaron a cabo estudios de acoplamiento molecular y simulaciones de dinámica molecular de 200 ns para evaluar la estabilidad de la unión. Las energías libres de unión se calcularon mediante MM‑GBSA.
Resultados: Se identificaron dieciséis dianas superpuestas y se priorizaron diez genes centrales. El análisis de acoplamiento mostró una afinidad de unión moderada de la colchicina para CYP3A4, TUBB1 y CYP2B6 (−6,9 a −7,4 kcal/mol). Las simulaciones de dinámica molecular indicaron complejos ligando‑proteína estables, con valores de RMSD inferiores a 2,5 Å. El análisis MM‑GBSA indicó energías de unión favorables, en particular para TUBB1.
Conclusiones: La colchicina podría interactuar con múltiples dianas relacionadas con la ISR y proporcionar una base computacional para estudios posteriores de validación experimental.
Palabras Clave: acoplamiento molecular; dinámica molecular; farmacología de redes; reestenosis intrastent; reposicionamiento de fármacos.

Citation Format: Suryono S, Amien MI, Tohari AI, Saputra AD, Hidayat MRF, Hibatullah MN, Ramadhan HF, Hibatulloh MF (2026) Integrated network pharmacology and molecular simulation analysis of colchicine in coronary in-stent restenosis. J Pharm Pharmacogn Res 14(4): 2545. https://doi.org/10.56499/jppres_14.4.2545
References
Adu-Amankwaah J, Adzika GK, Adekunle AO, Ndzie Noah ML, Mprah R, Bushi A, Akhter N, Huang F, Xu Y, Adzraku SY, Nadeem I, Sun H (2021) ADAM17, a key player of cardiac inflammation and fibrosis in heart failure development during chronic catecholamine stress. Front Cell Dev Biol 9: 732952. https://doi.org/10.3389/fcell.2021.732952
Alfonso F, Coughlan JJ, Giacoppo D, Kastrati A, Byrne RA (2022) Management of in-stent restenosis. EuroIntervention 18: E103–E123. https://doi.org/10.4244/EIJ-D-21-01034
Amien MI, Nurhidayat BR, Rizqa SU, Arfiani SZ, Widiastuti LN, Isbach GP (2026) Computational design of a novel chimeric multi-epitope vaccine against chlamydia trachomatis serovar a to prevent trachoma. Braz J Microbiol 57: 160. https://doi.org/10.1007/s42770-026-01977-x
Asgarbeik S, Vahidi A, Hasanzad M, Asadi M, Amoli MM (2022) Vascular endothelial growth factor genetic variant is associated with in-stent restenosis after percutaneous coronary intervention. J Tehran Univ Heart Cent 17: 119–126. https://doi.org/10.18502/jthc.v17i3.10844
Buccheri D, Piraino D, Andolina G, Cortese B (2016) Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis 8: E1150–E1162. https://doi.org/10.21037/jtd.2016.10.93
Cao X, Zao X, Xue B, Chen H, Zhang J, Li S, Li X, Zhu S, Guo R, Li X, Ye Y (2021) The mechanism of TiaoGanYiPi formula for treating chronic hepatitis B by network pharmacology and molecular docking verification. Sci Rep 11: 8402. https://doi.org/10.1038/s41598-021-87812-9
Case DA, Aktulga HM, Belfon K, Cerutti DS, Cisneros GA, Cruzeiro VWD, Forouzesh N, Giese TJ, Götz AW, Gohlke H, Izadi S, Kasavajhala K, Kaymak MC, King E, Kurtzman T, Lee TS, Li P, Liu J, Luchko T, Merz KM (2023) AmberTools. J Chem Inf Model 63: 6183–6191. https://doi.org/10.1021/acs.jcim.3c01153
Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A (2015) Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. Eur Heart J 36: 94–99. https://doi.org/10.1093/eurheartj/ehu383
Curcio A, Torella D, Indolfi C (2011) Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: Approach to therapy. Circ J 75: 1287–1296. https://doi.org/10.1253/circj.CJ-11-0366
Feng A, Caro YM, Gardner C, Grischo G, Liang Y, Wickremasinghe PD, Polmann M, Kala M, Marlowe T, Black SM, Knox KS, Wang T (2023) PTK2-associated gene signature could predict the prognosis of IPF. Respir Res 24: 304. https://doi.org/10.1186/s12931-023-02582-4
Florek K, Mendyka D, Gomułka K (2024) Vascular endothelial growth factor (VEGF) and its role in the cardiovascular system. Biomedicines 12: 1055. https://doi.org/10.3390/biomedicines12051055
Han Z, Wu X, Gao Y, Liu X, Bai J, Gu R, Lan RF, Xu B, Xu W (2020) PDK1–AKT signaling pathway regulates the expression and function of cardiac hyperpolarization-activated cyclic nucleotide-modulated channels. Life Sci 250: 117546. https://doi.org/10.1016/j.lfs.2020.117546
Hijazi M, Wilkins DM, Ceriotti M (2018) Fast-forward Langevin dynamics with momentum flips. J Chem Phys 148: 184109. https://doi.org/10.1063/1.5029833
Jo S, Kim T, Iyer VG, Im W (2008) CHARMM-GUI: A web-based graphical user interface for CHARMM. J Comput Chem 29: 1859–1865. https://doi.org/10.1002/jcc.20945
Kim S, Chen J, Cheng T, Gindulyte A, He J, He S, Li Q, Shoemaker BA, Thiessen PA, Yu B, Zaslavsky L, Zhang J, Bolton EE (2023) PubChem 2023 update. Nucleic Acids Res 51: D1373–D1380. https://doi.org/10.1093/nar/gkac956
Martínez L (2015) Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis. PloS ONE 10: e0119264. https://doi.org/10.1371/journal.pone.0119264
Park DW, Hong MK, Mintz GS, Lee CW, Song JM, Han KH, Kang DH, Cheong SS, Song JK, Kim JJ, Weissman NJ, Park SW, Park SJ (2006) Two-year follow-up of the quantitative angiographic and volumetric intravascular ultrasound analysis after nonpolymeric paclitaxel-eluting stent implantation: Late “catch-up” phenomenon from ASPECT study. J Am Coll Cardiol 48: 2432–2439. https://doi.org/10.1016/j.jacc.2006.08.033
Patel S, Brooks CL III (2004) CHARMM fluctuating charge force field for proteins: I parameterization and application to bulk organic liquid simulations. J Comput Chem 25: 1–15. https://doi.org/10.1002/jcc.10355
Patel T, Rahimi N, Cassagnol M (2026) Biochemistry, Cytochrome P450. In: StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL). https://www.ncbi.nlm.nih.gov/books/NBK557698/
Phillips JC, Hardy DJ, Maia JDC, Stone JE, Ribeiro JV, Bernardi RC, Buch R, Fiorin G, Hénin J, Jiang W, McGreevy R, Melo MCR, Radak BK, Skeel RD, Singharoy A, Wang Y, Roux B, Aksimentiev A, Luthey-Schulten Z, Tajkhorshid E (2020) Scalable molecular dynamics on CPU and GPU architectures with NAMD. J Chem Phys 153: 044130. https://doi.org/10.1063/5.0014475
Suryono S, Amien MI, Tohari AI, Saputra AD, Hidayat MR, Ramadhan HF (2025) In silico studies on quercetin, myricetin, and kaempferol in inhibiting TGF-β1 and galectin-3 for cardiac fibrosis management. Narra J 5: e1310. https://doi.org/10.52225/narra.v5i1.1310
Suryono S, Rohman MS, Widjajanto E, Prayitnaningsih S, Wihastuti TA, Oktaviono YH (2023) Effect of colchicine in reducing MMP-9, NOX2, and TGF-β1 after myocardial infarction. BMC Cardiovasc Disord 23: 449. https://doi.org/10.1186/s12872-023-03464-9
Trott O, Olson AJ (2010) AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455–461. https://doi.org/10.1002/jcc.21334
Verschuren JJW, Trompet S, Postmus I, Sampietro ML, Heijmans BT, Houwing-Duistermaat JJ, Slagboom PE, Jukema JW (2012) Systematic testing of literature reported genetic variation associated with coronary restenosis: Results of the GENDER study. PLoS One 7: e42401. https://doi.org/10.1371/journal.pone.0042401
Wang Z, Zhao YT, Zhao TC (2021) Histone deacetylases in modulating cardiac disease and their clinical translational and therapeutic implications. Exp Biol Med 246: 213–225. https://doi.org/10.1177/1535370220944128
Younas A, Awan Z, Khan T, Mehta S, Munir A, Raja HAA, Jain H, Raza A, Sehar A, Ahmed R, Nashwan AJ (2025) The effect of colchicine on myocardial infarction: An updated systematic review and meta-analysis of randomized controlled trials. Curr Probl Cardiol 50: 102878. https://doi.org/10.1016/j.cpcardiol.2024.102878
Zhang DM, Chen S (2020) In-stent restenosis and a drug-coated balloon: Insights from a clinical therapeutic strategy on coronary artery diseases. Cardiol Res Pract 2020: 8104939. https://doi.org/10.1155/2020/8104939
Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S (2021) Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci 22: 12808. https://doi.org/10.3390/ijms222312808
© 2026 Journal of Pharmacy & Pharmacognosy Research